Introduction
Estrogen-containing medications were first approved by the United States Food and Drug Administration in 1941. 1 Estrogen-only hormone replacement therapy (also referred to as unopposed HRT) was widely used to treat menopause symptoms until the mid1970s, when new studies emerged linking therapy to an increased risk of endometrial cancer. 2, 3 HRT use declined until the early 1980s, at which time progestin was added to estrogen therapy (known as combination HRT) to reduce endometrial cancer risk in women who had not had a hysterectomy. With the introduction of combination therapy, HRT use again increased, exceeding previous highs of the mid-1970s. [4] [5] [6] New evidence on HRT benefits and risks continued to emerge throughout the 1990s and 2000s, contributing to divergent usage patterns. An increase in use persisted throughout the 1990s following the publication of studies and guidelines on HRT's benefit in reducing the risk of coronary heart disease and hip fractures. 7, 8 Later in the decade, new studies reported on HRT's lack of benefit for the secondary prevention of coronary heart disease and its linkage to an increased risk of breast cancer. [9] [10] [11] [12] [13] [14] In the early 2000s HRT use began to decline, following publication of the 2002 Women's Health Initiative (WHI) study. This study concluded that overall health risks exceeded benefits from the use of combination HRT among healthy, post-menopausal women and that this regimen not be used for primary prevention of coronary heart disease. 15 A later WHI study looking at estrogen-only HRT concluded that there was no overall benefit to this regimen and that it not be recommended for chronic disease prevention in post-menopausal women. 16 The WHI study results prompted regulatory bodies and professional associations to revise safety information and practice guidelines regarding HRT prescribing, shifting from cardiovascular disease prevention to therapeutic use of HRT. [16] [17] [18] [19] [20] [21] [22] [23] In Canada, HRT prescribing is addressed in clinical practice guidelines of the Society of Obstetricians and Gynaecologists of Canada (SOGC) from the Canadian Consensus Conference on Menopause, 2006 Update 20 and the Canadian Consensus Conference on Osteoporosis, 2006 Update. 21 The menopause guidelines recommend that the primary indication for HRT be to manage moderate to severe menopause symptoms, and that it be prescribed at the lowest effective dose and for the appropriate duration to achieve the treatment goals, considering the potential risks and benefits to the patient. The osteoporosis guidelines recommend that patient risks be weighed against the benefits if HRT is being used solely for fracture prevention.
In September 2007, CIHI released an analysis that showed oral conjugated estrogens, commonly part of HRT regimens, were one of the fastest-declining drug classes considered to be potentially inappropriate to prescribe to women over the age of 65 (hereafter referred to as "seniors") based on the 2003 Beers criteria. 24 The following analysis examines trends in HRT use in female seniors in five Canadian provinces from April 1, 2000, to March 31, 2007 . The study period begins as new evidence on HRT risks was starting to emerge and follows trends as additional studies were published and practice guidelines were updated.
Methods

Claims Data Source
The drug claims data used in this analysis come from the National Prescription Drug Utilization Information System (NPDUIS) database, as submitted by the Alberta, Saskatchewan, Manitoba, New Brunswick and Nova Scotia provincial public drug programs. The NPDUIS database houses pan-Canadian information related to public program formularies, drug claims, policies and population statistics. It was designed to provide information that supports accurate, timely and comparative analytic and reporting requirements for the establishment of sound pharmaceutical policies and the effective management of Canada's public drug benefit programs.
The NPDUIS database includes:
• Claims accepted by public drug programs, either for reimbursement or toward a deductible. Claims are included regardless of whether or not the patient actually used the drugs.
The NPDUIS database does not include information regarding:
• Prescriptions that were written but never dispensed;
• Prescriptions that were dispensed but for which the associated drug costs were not submitted to, or not accepted by, the public drug programs; or • Diagnosis or condition for which prescriptions were written.
Data Comparability
Age Standardization:
Provincial rates were age-standardized using a direct method of standardization based on the October 1, 2006, Canadian female senior population. The age groups used for standardization were 65 to 74, 75 to 84 and 85 years and older. 
Drug Plan Comparison:
Although public drug coverage is available to seniors in all five provinces included in the analysis, each of their drug plans is designed differently. These differences may impact drug utilization within the plans and, in turn, the claims submitted to the NPDUIS database. One main difference is that seniors in Manitoba and Saskatchewan are covered under universal drug plans, offered to residents of all ages, whereas Alberta, New Brunswick and Nova Scotia all have drug plans designed specifically for seniors. There are also other differences, such as how much a senior is required to pay for drugs and how Further information about public drug programs in Canada can be found in the NPDUIS Plan Information Document, available at http://secure.cihi.ca/cihiweb/dispPage.jsp?cw_ page=GR_1302_E.
Formulary Comparison:
Differences in the coverage of drugs on provincial formularies can lead to differences in drug utilization, and are identified to provide context when conducting interprovincial comparisons. The benefit status of HRT drugs is quite similar in the five drug programs, with few exceptions. The most noticeable difference in formulary coverage was related to transdermal HRT products (that is, patches and gels). These products were listed as full benefits in Alberta; were restricted to patients who were intolerant to oral HRT products in Saskatchewan, Manitoba and Nova Scotia; and were listed as both full benefits and restricted benefits in New Brunswick, depending on the product. Because the use of these products was relatively low (only 14.2% of HRT users had claims for transdermal products) it was concluded that differences in formulary coverage had little impact on HRT use, as a whole, in the five drug programs.
Drugs of Interest
HRT products were identified by the drug identification number (DIN) assigned by Health Canada, and the following World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification codes: G03C-Estrogens, G03D-Progestogens and G03F-Estrogens and Progestogens in Combination. The term "progestogens" refers to a class of products that includes both progesterones and progestins.
The HRT products included in the analysis were oral and transdermal preparations indicated for the management of a broad range of menopause symptoms, as well as for the prevention of osteoporosis. Progestogen products were only included if they were used in combination with an estrogen product.
Definitions
1. "HRT users" refers to seniors who claimed a hormone replacement therapy product at least once during a given year. HRT users are further categorized as either "Combination HRT users" or "Estrogen-only HRT users" as defined below.
2. "Combination HRT users" refers to seniors who either claimed an estrogen product and a progestogen product, or claimed a product containing a combination of estrogen and progestogen, at least once in a given year.
3. "Estrogen-only HRT users" refers to seniors who claimed an estrogen product at least once in a given year, without claiming either a progestogen product or a product containing a combination of estrogen and progestogen in that same year.
Limitations
Since the NPDUIS database does not contain information regarding diagnosis or condition for which prescriptions were written, it is not known whether the HRT claims were related to the treatment of menopausal symptoms, to prevent osteoporosis or for another indication.
By focusing on seniors, this analysis examines only a small proportion of HRT use in Canada. While Canadian claims-level data for HRT use in females aged less than 65 years was unavailable for this study, a previous study looking at drug recommendations for HRT, made during Canadian women's visits to their physicians' offices, estimated that only a quarter of women for whom HRT was recommended were over the age of 60, and less than 5% were over the age of 70. 26 The ability to examine duration of therapy and long-term use was limited by the time horizon of the data (2000-2001 to 2006-2007) and the lack of consensus on the definition of long-term use. Current guidelines generally recommend shorter durations of HRT therapy, especially for combination regimens. Though there was no single definition of long-term HRT therapy, most references consider use beyond four to five years as long term. 27 Because this analysis focused on HRT use by seniors, the ability to measure treatment duration was further limited, as duration of HRT use by patients prior to turning 65 is unknown.
The lack of information on dosing instructions (for example, take two tablets, twice daily) and dispensed quantity units (for example, tablets or milligrams) presented challenges in examining dosage trends. To address these issues, the analysis of dose ( Figure 6 ) was restricted to oral conjugated estrogens, due to a higher consistency in the reporting of dispensed units and in dosing (typically, oral conjugated estrogen tablets for treating menopause symptoms are taken once daily). Oral conjugated estrogens also had the highest rate of use among HRT products, accounting for 75.7% of all female seniors with HRT claims in 2006-2007. Other studies examining drug quantities have limited their analysis to oral-solid dosage forms (for example, tablets), excluding products, like liquids or creams, which are known to have inconsistently reported quantity units. The proportion of female seniors who had drug claims accepted by the public drug programs in these provinces varied from 63.7% in New Brunswick to 92.8% in Manitoba. The lower percentages in New Brunswick and Nova Scotia may be related to plan design. Seniors not covered by the publicly funded drug plan may have a private drug plan or pay out of pocket. These proportions are only meant to reflect the relative size of the claimant populations, and should not be considered as measures of the extent of drug coverage in these provinces. It should be noted that the total population figures include seniors who are not eligible for provincial coverage, such as those covered under federal drug plans. It should also be noted that whereas total population figures are meant to reflect the population at a single point in time, claimant population figures reflect the number of people who made claims throughout a given year.
There is variation in the age distribution of female senior claimant populations of the five provinces. Saskatchewan has the highest proportion of claimants over the age of 85, at 21.7%, while Alberta has the smallest proportion of claimants over the age of 85, at 14.1% (see Appendix B).
Analysis Overview of HRT Claim Trends
The following analysis expands on CIHI's September 2007 analysis, which showed oral conjugated estrogens, commonly part of HRT regimens, were one of the fastest-declining drug classes considered to be potentially inappropriate to prescribe to women over the age of 65 (hereafter referred to as "seniors") based on the 2003 Beers criteria. 24 The study period begins as new evidence on HRT risks was starting to emerge and follows trends as additional studies were published and practice guidelines were updated. The number of HRT users declined at an average rate of 17.0% per year during the study period. The highest average annual rate of decline (30.0%) was in the two-year period following the publication of the Women's Health Initiative (WHI) study results in 2002. This is consistent with previous studies, which reported significant declines in HRT use following the release of the WHI study. 4, 30 The age-standardized, combined rate of HRT use iii among female seniors in all five provinces declined from 13. iii. For non-standardized rates, see Appendix C. There is a noticeable difference between the age of estrogen-only and combination HRT users in 2006-2007 ( Figure 5) ; 67.0% of senior estrogen-only HRT users are in the 65-to-74 age group, 27.5% in the 75-to-84 age group and 5.5% were aged 85 and older. A much higher percentage (79.9%) of combination HRT users was found in the 65-to-74 age group, resulting in a much lower percentage of users in the 75-to-84 (17.7%) and 85 and older (2.4%) age groups.
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Duration and Dose of HRT
Current Canadian menopause guidelines recommend that HRT be taken at the lowest effective dose and for the appropriate duration to achieve treatment goals. As noted previously, several factors limited analytic work on dose and duration of therapy.
HRT Duration:
Examining duration of treatment was difficult because of the limited time horizon of the data, as well as the lack of information regarding the length of time patients were using HRT prior to turning 65. 
HRT Dose:
Due to the lack of available information about dispensed quantity units, and complexities in progestogen dosing, analysis of HRT dose trends was limited to claims for oral conjugated estrogens. 
Route of Administration of HRT
The majority of female seniors had claims for oral HRT products (88.2% in 2006-2007), while 14.2% had claims for transdermal products, vi including patches and gels (a small proportion of patients had claims for both oral and transdermal products). Some studies have suggested that there is a reduced risk of venous thromboembolism (VTE) with transdermal products compared to oral therapy. 31 The majority of the decline in HRT use was with oral products. The use of oral-HRT products fell at an average annual rate of 18.0% per year, faster than the 7.6% average annual rate of decline in transdermal HRT product use (Figure 7) . Patients switching from oral to transdermal HRT products during the study period had little effect on these trends. Of patients using oral HRT products (and not using transdermal products 
Conclusion
The emergence of new evidence on the benefits and risks of hormone replacement therapy (HRT) throughout the past two decades has led to ongoing revisions to clinical practice guidelines on HRT use. Current Canadian menopause and osteoporosis guidelines recommend consideration of the potential risks and benefits to patients, whether prescribing HRT for menopausal symptoms or for fracture prevention. 20, 21 Canadian menopause guidelines also recommend the primary indication for HRT be to manage moderate to severe menopause symptoms, and that it be prescribed at the lowest effective dose and for the appropriate duration to achieve the treatment goals. Though this analysis provides some insight into how changes in evidence have affected HRT use in Canadian female seniors, several questions remain unanswered. Further analysis is needed to examine areas such as the effect the decline in HRT use has had on the use of non-hormonal therapies in the management of menopause symptoms, as well as therapies such as bisphosphonates, used for fracture prevention in postmenopausal women.
Appendix A-Drug Classification Systems
Drugs can be analyzed using many different classification systems. For the purposes of this analysis in brief, the following have been used:
• The drug identification number (DIN) as assigned by Health Canada. A DIN is specific to manufacturer, trade name, active ingredient(s), strength(s) of active ingredient(s) and pharmaceutical form. In this analysis, references to drug products are implied to be specific to DIN level.
• World Health Organization system of Anatomical Therapeutic Chemical (ATC) classifications as reported in the Health Canada Drug Product Database.
vii − In the ATC classification system, the drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutic properties. − The ATC does not distinguish between strength, dosage, route or form of drug, except as implied by the ATC (for example, inhaled corticosteroid). − Drugs are classified in groups at five different levels.
o The drugs are divided into 14 main groups (first level), with one pharmacological/therapeutic subgroup (second level).
o The third and fourth levels are chemical/pharmacological/therapeutic subgroups.
o The second, third and fourth levels are often used to identify pharmacological subgroups when that is considered more appropriate than therapeutic or chemical subgroups.
o The fifth level is the chemical substance.
vii. Although typically Health Canada assigns drug products to a fifth-level ATC, in some cases, it may assign an ATC at the fourth or even the third level. 
